Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Primary Myelofibrosis 1Pancreatic Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Surveys and Questionnaires 2Standard of Care 2Radiosurgery 2Practice Guidelines as Topic 2Oxaliplatin 2Nivolumab 2Leucovorin 2Fluorouracil 2tislelizumab 1irinotecan sucrosofate 1folfirinox 1fludarabine 1encorafenib 1durvalumab 1canakinumab 1avatrombopag 1aldesleukin 1Transurethral Resection of Prostate 1Sodium Chloride 1Restraint, Physical 1Remote Patient Monitoring 1Radiotherapy 1Psilocybin 1Poly(ADP-ribose) Polymerase Inhibitors 1Panitumumab 1Observation 1Massage 1Magnetic Resonance Spectroscopy 1Levoleucovorin 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastrointestinal Neoplasms × canakinumab × Clear all
NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡